These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 37545260)

  • 1. Outcome Measures for Disease-Modifying Trials in Parkinson's Disease: Consensus Paper by the EJS ACT-PD Multi-Arm Multi-Stage Trial Initiative.
    Gonzalez-Robles C; Weil RS; van Wamelen D; Bartlett M; Burnell M; Clarke CS; Hu MT; Huxford B; Jha A; Lambert C; Lawton M; Mills G; Noyce A; Piccini P; Pushparatnam K; Rochester L; Siu C; Williams-Gray CH; Zeissler ML; Zetterberg H; Carroll CB; Foltynie T; Schrag A;
    J Parkinsons Dis; 2023; 13(6):1011-1033. PubMed ID: 37545260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient and Public Involvement and Engagement in the Development of a Platform Clinical Trial for Parkinson's Disease: An Evaluation Protocol.
    Zeissler ML; Bakshi N; Bartlett M; Batla A; Byrom D; Chapman R; Collins S; Cowd E; Deeson E; Ellis-Doyle R; Forbes J; Gonzalez-Robles C; Jewell A; Lane EL; LaPelle NR; Martin K; Matthews H; Miller L; Mills G; Morgan A; Parry M; Pushparatnam K; Ratcliffe N; Salathiel D; Scurfield P; Siu C; Whipps S; Wonnacott S; Foltynie T; Carroll CB; McFarthing K;
    J Parkinsons Dis; 2024; 14(4):809-821. PubMed ID: 38701161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global--clinical evaluations, serum biomarkers, genetic studies and neuroimaging--prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression.
    Santos-García D; Mir P; Cubo E; Vela L; Rodríguez-Oroz MC; Martí MJ; Arbelo JM; Infante J; Kulisevsky J; Martínez-Martín P;
    BMC Neurol; 2016 Feb; 16():26. PubMed ID: 26911448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling of Parkinson's Disease Progression and Implications for Detection of Disease Modification in Treatment Trials.
    Ribba B; Simuni T; Marek K; Siderowf A; Diack C; Pierrillas PB; Monnet A; Ricci B; Nikolcheva T; Pagano G
    J Parkinsons Dis; 2024; 14(6):1225-1235. PubMed ID: 39058452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is It Possible to Conduct a Multi-Arm Multi-Stage Platform Trial in Parkinson's Disease: Lessons Learned from Other Neurodegenerative Disorders and Cancer.
    Zeissler ML; Li V; Parmar MKB; Carroll CB
    J Parkinsons Dis; 2020; 10(2):413-428. PubMed ID: 32116263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards a multi-arm multi-stage platform trial of disease modifying approaches in Parkinson's disease.
    Foltynie T; Gandhi S; Gonzalez-Robles C; Zeissler ML; Mills G; Barker R; Carpenter J; Schrag A; Schapira A; Bandmann O; Mullin S; Duffen J; McFarthing K; Chataway J; Parmar M; Carroll C;
    Brain; 2023 Jul; 146(7):2717-2722. PubMed ID: 36856727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Embedding Patient Input in Outcome Measures for Long-Term Disease-Modifying Parkinson Disease Trials.
    Gonzalez-Robles C; Bartlett M; Burnell M; Clarke CS; Haar S; Hu MT; Huxford B; Jha A; Lawton M; Noyce A; Piccini P; Pushparatnam K; Rochester L; Siu C; van Wamelen D; Williams-Gray CH; Zeissler ML; Zetterberg H; Carroll CB; Foltynie T; Weil RS; Schrag A;
    Mov Disord; 2024 Feb; 39(2):433-438. PubMed ID: 38140767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An International Multi-Stakeholder Delphi Survey Study on the Design of Disease Modifying Parkinson's Disease Trials.
    Zeissler ML; McFarthing K; Raphael KG; Rafaloff G; Windle R; Carroll CB
    J Parkinsons Dis; 2023; 13(8):1343-1356. PubMed ID: 38007672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caregiver burden in Parkinson's disease: a mixed-methods study.
    Geerlings AD; Kapelle WM; Sederel CJ; Tenison E; Wijngaards-Berenbroek H; Meinders MJ; Munneke M; Ben-Shlomo Y; Bloem BR; Darweesh SKL
    BMC Med; 2023 Jul; 21(1):247. PubMed ID: 37424022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.
    Parashos SA; Luo S; Biglan KM; Bodis-Wollner I; He B; Liang GS; Ross GW; Tilley BC; Shulman LM;
    JAMA Neurol; 2014 Jun; 71(6):710-6. PubMed ID: 24711047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy--a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group.
    Schenck CH; Montplaisir JY; Frauscher B; Hogl B; Gagnon JF; Postuma R; Sonka K; Jennum P; Partinen M; Arnulf I; Cochen de Cock V; Dauvilliers Y; Luppi PH; Heidbreder A; Mayer G; Sixel-Döring F; Trenkwalder C; Unger M; Young P; Wing YK; Ferini-Strambi L; Ferri R; Plazzi G; Zucconi M; Inoue Y; Iranzo A; Santamaria J; Bassetti C; Möller JC; Boeve BF; Lai YY; Pavlova M; Saper C; Schmidt P; Siegel JM; Singer C; St Louis E; Videnovic A; Oertel W
    Sleep Med; 2013 Aug; 14(8):795-806. PubMed ID: 23886593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How should future clinical trials be designed in the search for disease-modifying therapies for Parkinson's disease?
    Lenka A; Jankovic J
    Expert Rev Neurother; 2023 Feb; 23(2):107-122. PubMed ID: 36803618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive training interventions for dementia and mild cognitive impairment in Parkinson's disease.
    Orgeta V; McDonald KR; Poliakoff E; Hindle JV; Clare L; Leroi I
    Cochrane Database Syst Rev; 2020 Feb; 2(2):CD011961. PubMed ID: 32101639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2024 Update.
    McFarthing K; Buff S; Rafaloff G; Pitzer K; Fiske B; Navangul A; Beissert K; Pilcicka A; Fuest R; Wyse RK; Stott SRW
    J Parkinsons Dis; 2024; 14(5):899-912. PubMed ID: 39031388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression of motor and nonmotor features of Parkinson's disease and their response to treatment.
    Vu TC; Nutt JG; Holford NH
    Br J Clin Pharmacol; 2012 Aug; 74(2):267-83. PubMed ID: 22283961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parkinson's Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson's Disease Progression.
    Brumm MC; Siderowf A; Simuni T; Burghardt E; Choi SH; Caspell-Garcia C; Chahine LM; Mollenhauer B; Foroud T; Galasko D; Merchant K; Arnedo V; Hutten SJ; O'Grady AN; Poston KL; Tanner CM; Weintraub D; Kieburtz K; Marek K; Coffey CS;
    J Parkinsons Dis; 2023; 13(6):899-916. PubMed ID: 37458046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson's Disease: The International Linked Clinical Trials Initiative.
    Wyse RK; Isaacs T; Barker RA; Cookson MR; Dawson TM; Devos D; Dexter DT; Duffen J; Federoff H; Fiske B; Foltynie T; Fox S; Greenamyre JT; Kieburtz K; Kordower JH; Krainc D; Matthews H; Moore DJ; Mursaleen L; Schwarzschild MA; Stott SRW; Sulzer D; Svenningsson P; Tanner CM; Carroll C; Simon DK; Brundin P
    J Parkinsons Dis; 2024; 14(4):657-666. PubMed ID: 38578902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining meaningful outcome measures in trials of disease-modifying therapies in Parkinson's disease.
    Evans JR; Barker RA
    Expert Opin Pharmacother; 2011 Jun; 12(8):1249-58. PubMed ID: 21345151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson's disease.
    Odin P; Chaudhuri KR; Volkmann J; Antonini A; Storch A; Dietrichs E; Pirtošek Z; Henriksen T; Horne M; Devos D; Bergquist F
    NPJ Parkinsons Dis; 2018; 4():14. PubMed ID: 29761156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.